Journals / Cukurova Medical Journal / 2019 / Cilt: 44 - Sayı: 1

Effect of neoadjuvant chemotherapy on estrogen receptor, progesterone receptor, Cerb-B2, vascular endothelial growth factor and Ki-67 in patients with locally advanced breast cancer

Lokal ileri evre meme kanserli hastalarda, neoadjuvan kemoterapinin östrojen reseptörleri, progesterone reseptörleri, Cerb-B2, vasküler endotelyal büyüme faktörü ve Ki-67 üzerine etkisi

Pages
226–231
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The significant change in the Ki-67proliferation index may suggest the reduced proliferativeactivity of malignant cells with neoadjuvant chemotherapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: The aim of this study is aimed to demonstratethe changes in the tumor diameter and expressions ofvascular endothelial growth factor (VEGF), estrogenreceptor (ER), progesterone receptor (PR), Ki-67, andCerb-B2 status after neoadjuvant chemotherapy in thepatients with locally advanced breast cancer.Materials and Methods: Sixty-nine patients whodiagnosed with locally advanced breast cancer and treatedwith were prospectively evaluated.
📊
Key Findings & Data:The tumor diameterand VEGF, Ki-67, ER, PR, and Cerb-B2 expressionstested by immunohistochemistry (IHC) were evaluatedbefore and after neoadjuvant chemotherapy.Results: There was a statistically significant reduction inthe tumor diameter and in the expression of VEGF, Ki67, ER, PR, and Cerb-B2 after neoadjuvant chemotherapy.Conclusion: The significant reduction in VEGFexpression suggests that the tumor angiogenesis and itsmetastatic ability may be reduced by neoadjuvantchemotherapy.
💡
Conclusion & Impact:The significant change in the Ki-67proliferation index may suggest the reduced proliferativeactivity of malignant cells with neoadjuvant chemotherapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: The aim of this study is aimed to demonstratethe changes in the tumor diameter and expressions ofvascular endothelial growth factor (VEGF), estrogenreceptor (ER), progesterone receptor (PR), Ki-67, andCerb-B2 status after neoadjuvant chemotherapy in thepatients with locally advanced breast cancer.Materials and Methods: Sixty-nine patients whodiagnosed with locally advanced breast cancer and treatedwith were prospectively evaluated. The tumor diameterand VEGF, Ki-67, ER, PR, and Cerb-B2 expressionstested by immunohistochemistry (IHC) were evaluatedbefore and after neoadjuvant chemotherapy.Results: There was a statistically significant reduction inthe tumor diameter and in the expression of VEGF, Ki67, ER, PR, and Cerb-B2 after neoadjuvant chemotherapy.Conclusion: The significant reduction in VEGFexpression suggests that the tumor angiogenesis and itsmetastatic ability may be reduced by neoadjuvantchemotherapy. The significant change in the Ki-67proliferation index may suggest the reduced proliferativeactivity of malignant cells with neoadjuvant chemotherapy.

Özet

Amaç: Bu çalışmada lokal ileri evre meme kanserli hastalarda neoadjuvan kemoterapi ile tümör çapı, tümörlü dokuda çalışılan vasküler endotelyal büyüme faktörü (VEGF), östrojen reseptörü (ER), progesteron reseptörü (PR), Ki-67 ve Cerb-B2 ekspresyonlarındaki değişimin gösterilmesi amaçlanmıştır. Gereç ve Yöntem: Çukurova Üniversitesi Tıp Fakültesi Genel Cerrahi ve Tıbbi Onkoloji Bilim Dalı’nda 2008 ve 2013 yılları arasında lokal ileri meme kanseri nedeniyle tedavi gören 69 hastanın verileri prospektif olarak araştırılmıştır. Tümör çapı, tümörlü dokuda çalışılan VEGF, Ki-67, ER, PR ve Cerb-B2 ekspresyonları immunhistokimyasal (İHK) yöntem ile neoadjuvan kemoterapi öncesi ve sonrası dönemde karşılaştırmalı olarak değerlendirilmiştir. Bulgular: Neoadjuvan kemoterapi sonrası tümör çapı, VEGF, Ki-67, ER, PR ve Cerb-B2 ekspresyonlarında istatistiksel olarak anlamlı düşüş saptandı. Sonuç: Tümör dokusunda çalışılan VEGF düzeyindeki anlamlı düşme, tümörün anjiyogenezinin ve bu yolla metastaz yapabilme yeteneğinin neoadjuvan kemoterapi etkisiyle azalabileceği sonucunu telkin etmektedir. Tümör dokusunda çalışılan Ki-67 proliferasyon indeksinde anlamlı değişim; malign hücre proliferasyonunun neoadjuvan kemoterapi etkisiyle azaldığını gösterebilir.

🔖

Cite This Article

Paydaş, S., Ergin, M., Zorludemir, S., Kekeç, Y., Sakman, G., Yalav, O., Kılıç, E. B., Sarıtaş, A. G., Eray, İ. C., Kara, İ. O. (2022). Effect of neoadjuvant chemotherapy on estrogen receptor, progesterone receptor, Cerb-B2, vascular endothelial growth factor and Ki-67 in patients with locally advanced breast cancer. Cukurova Medical Journal, Cilt: 44 - Sayı: 1, 226–231. https://ajindex.com/articles/476803

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Jatoi I. Breast cancer: a systemic or local disease? Am J ClinOncol. 1997;20:536-9
  2. Teshome M, Hunt K,. Neoadjuvant therapy in the treatment of breast cancer. Surg Oncol Clin N Am. 2014;23:505–23
  3. Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 2007;94:1189-200
  4. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer:a meta-analysis. J Natl Cancer Inst. 2005;97:188–94
  5. Lee MC, Newman LA. Management of patients with locally advanced breast cancer. Surg Clin North Am. 2007;87:379-98
  6. Wolff AC, Davidson NE. Preoperative therapy in breast cancer: lessons from the treatment of locally advanced disease. Oncologist. 2002;7:239-45
  7. Buchholz TA, Hunt KK, Whitman GJ, Sahin AA, Hortobagyi GN. Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer. 2003;98:1150-60
  8. Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609-18
  9. Güler N, Karabulut B, Koçdor MA, Kaya H, Esen G, Özaslan C et al. Locally advanced breast cancer2010 Istanbul breast cancer consensus meeting. Journal of Breast Health. 2011:7;68-85
  10. Mamounas EP, Fisher B. Preoperative (neoadjuvant) chemotherapy in patients with breast cancer. Semin Oncol. 2001;28:389–99
  11. Edge SB, Byrd DR, Compton CC, Fritz AG, Grene FI, Trotti A. Breast in AJCC Cancer Staging Manual. Seventh Edition. Chicago, IL, Springer, 2010
  12. Kim EA, Gershtein ES, Vyotskaya IV, Kushlinskii NE. Expression of VEGF and VEGFR2 in tumors during neoadjuvant therapy of patients with breast cancer. Bull Exp Biol Med. 2008;145:245-8
  13. Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer. 2005;92:147-55
  14. Arens N, Bleyl U, Hildenbrand R. HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virchows Arch. 2005;446:489-96 15. Koda M, Sulkowska M, Koda KL et al. The effect of chemotherapy on Ki-67, Bcl-2 and Bak expression in primary tumors and lymph node metastases of breast cancer. Oncol Rep. 2007;18:113-9
  15. Dede DS, Gumuskaya B, Guler G, Onat D, Al